Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06052176 · ClinicalTrials.gov registry record · Phase 2
Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement
A Phase 2 study of Cirrhosis and Hepatic Encephalopathy, sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06052176: Recruiting Phase 2 study of Cirrhosis and Hepatic Encephalopathy, sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center.
NCT06052176 is a Phase 2 study of Cirrhosis and Hepatic Encephalopathy that is actively recruiting participants, run by Hunter Holmes Mcguire Veteran Affairs Medical Center. The registered enrollment target is 30 participants, below the 90,408-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06052176, a Phase 2 study of Cirrhosis and Hepatic Encephalopathy, is actively recruiting participants, sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Hypothesis: Improvement in cognitive dysfunction with IV albumin in patients with cirrhosis with prior HE and MHE lasts for several weeks after albumin infusion has ended, and is due to persistent improvement in inflammatory markers, endothelial dysfunction, albumin function and gut microbial changes. This will be a single-arm, single-blind sequential trial of IV 25% albumin and IV saline over 8 weeks with biological sampling and cognitive and health related quality of life (HRQOL) testing with each subject acting as their own control.
Primary Outcome
cognitive improvement (PHES score ranges from -15 to 5), higher is good
Conditions Studied
Interventions
- DRUG Albumin Infusion
Study Locations (1)
Virginia
- Hunter Holmes McGuire VA Medical Center - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-11-02 |
| Est. Completion | 2026-10-01 |
| Phase | Phase 2 |
What NCT06052176 shows while recruiting
NCT06052176 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 90,408-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Cirrhosis appearing as the primary indexed condition, and to 1 intervention - of which Albumin Infusion is the first listed.
NCT06052176 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06052176 about?
NCT06052176 is a clinical study titled "Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement". Hypothesis: Improvement in cognitive dysfunction with IV albumin in patients with cirrhosis with prior HE and MHE lasts for several weeks after albumin infusion has ended, and is due to persistent improvement in inflammatory markers, endothelial dysfunction, albumin function and gut microbial change...
What is the current status of trial NCT06052176?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2023-11-02. Estimated completion is 2026-10-01.
What conditions does trial NCT06052176 study?
This clinical trial studies the following conditions: Cirrhosis, Hepatic Encephalopathy.
What interventions are being tested in trial NCT06052176?
The interventions under investigation include: Albumin Infusion (DRUG).
Who is sponsoring clinical trial NCT06052176?
This trial is sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06052176 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06052176's enrollment target sits among peer trials
30 31st of 53 higher than 13 of 53 other Cirrhosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cirrhosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
RECRUITING · Phase 2
-
Statin and Beta Blocker Use in Patients With Decompensated Cirrhosis
RECRUITING · Phase 2
-
Empagliflozin in Patients With Cirrhosis and Ascites
RECRUITING · Phase 2
-
Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI